Limnopharma 

Novel treatments for disabling ophthalmic diseases

OWNER

Limnopharma SL (See Profile)

Sector

Therapeutics

Stage

In vitro, proof of concept

Country

Spain


Potential first treatment available for several types of Retinitis Pigmentosa and for dry-AMD

Limnopharma first product will be administered without requiring medical assistance (eye drops administration)

Derivative of a natural product: well studied and low toxicity profile

This information is confidential, do not share or copy.

Under evaluation at least till:24th September

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2019 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar